Today’s Research Reports on Aralez Pharmaceuticals, Knight Therapeutics, Spectral Medical and Valeant Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / February 12, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.
RDI has Initiated Coverage Today on:
Aralez Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=ARZ.TO
Knight Therapeutics Inc.
https://rdinvesting.com/news/?ticker=GUD.TO
Spectral Medical Inc.
https://rdinvesting.com/news/?ticker=EDT.TO
Valeant Pharmaceuticals International, Inc.
https://rdinvesting.com/news/?ticker=VRX.TO
Aralez Pharmaceuticals' stock moved 1.36% lower Friday, to close the day at $2.17. The stock recorded a trading volume of 16,800 shares, which was below its three months average volume of 34,880 shares. In the last year, Aralez Pharmaceuticals' shares have traded in a range of 1.20 - 6.11. The share price has gained 80.83% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $2.18 is greater than its 200-day moving average of $1.96. Shares of Aralez Pharmaceuticals have gained approximately 21.23 percent year-to-date.
Access RDI's Aralez Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ARZ.TO
On Friday, shares of Knight Therapeutics recorded a trading volume of 310,864 shares, which was above the three months average volume of 249,327 shares. The stock ended the day 1.07% higher at 7.53. The stock is currently trading 31.55% below its 52-week high with a 52-week trading range of 7.38 - 11.00. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $7.89 is below its 200-day moving average of $8.30. Shares of Knight Therapeutics are trading at a Price to Earnings ratio of 60.24. Shares of Knight Therapeutics have fallen approximately 9.39 percent year-to-date.
Access RDI’s Knight Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=GUD.TO
Spectral Medical's stock moved 2.86% higher Friday, to close the day at $0.36. The stock recorded a trading volume of 88,158 shares, which was above its three months average volume of 87,690 shares. In the last year, Spectral Medical's shares have traded in a range of 0.23 - 0.64. The share price has gained 56.52% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.39 is greater than its 200-day moving average of $0.38. Shares of Spectral Medical have fallen approximately 5.26 percent year-to-date.
Access RDI's Spectral Medical Inc. Research Report at:
https://rdinvesting.com/news/?ticker=EDT.TO
On Friday, shares of Valeant Pharmaceuticals recorded a trading volume of 2,757,229 shares, which was above the three months average volume of 2,340,611 shares. The stock ended the day 1.63% higher at 22.41. The share price has gained 100.09% from its 52-week low with a 52-week trading range of 11.20 - 30.56. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $26.18 is greater than its 200-day moving average of $20.66. Shares of Valeant Pharmaceuticals are trading at a Price to Earnings ratio of 5.72. Shares of Valeant Pharmaceuticals have fallen approximately 14.47 percent year-to-date.
Access RDI's Valeant Pharmaceuticals International, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=VRX.TO
Our Actionable Research on Aralez Pharmaceuticals Inc. (TSX:ARZ.TO), Knight Therapeutics Inc. (TSX:GUD.TO), Spectral Medical Inc. (TSX:EDT.TO) and Valeant Pharmaceuticals International, Inc. (TSX:VRX.TO) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
